SCHEMBL20439472

SCHEMBL20439472

CC(C)(C)OC(=O)N1CC(c2nc3ccc(Br)cc3c(=O)[nH]2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.42
USP30 Q70CQ3 2/20 0.42
GAA P10253 1/20 0.40
MAPT P10636 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
ROCK2 O75116 1/20 0.40
FPR2 P25090 2/20 0.39
HPGDS O60760 2/20 0.39
RORC P51449 2/20 0.39
HCAR1 Q9BXC0 1/20 0.38
PARP1 P09874 1/20 0.38
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38
TUBA3C P0DPH7 1/20 0.38
TUBA1B P68363 1/20 0.38
TUBA4A P68366 1/20 0.38
TUBB4B P68371 1/20 0.38
TUBB3 Q13509 1/20 0.38
TUBB2A Q13885 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22701202 0.92 HPGDS (0.49) KDM4EUSP30MAPTROCK2FPR2
SCHEMBL23293923 0.90 KDM4E (0.47) KDM4EUSP30MAPTNPSR1ROCK2
SCHEMBL30947729 0.90 KDM4E (0.47) KDM4EUSP30MAPTNPSR1ROCK2
SCHEMBL20444734 0.86 CHEK2 (0.44) KDM4EUSP30BACE1ALDH1A1
SCHEMBL26911916 0.85 HPGDS (0.46) KDM4EHPGDSPARP1
SCHEMBL18020256 0.83 HCRTR1 (0.47) USP30GAAMAPTNPSR1RXFP1
SCHEMBL1853217 0.82 PIM1 (0.62)
SCHEMBL26170030 0.79 NAMPT (0.51) BACE1
SCHEMBL19385385 0.78 HPGDS (0.48) KDM4EUSP30MAPTHPGDSALDH1A1
SCHEMBL30186938 0.77 NSD2 (0.47) USP30MAPTFPR2BACE1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2018140514-A1 1-(6-(3-HYDROXYNAPHTHALEN-1-YL)QUINAZOLIN-2-YL)AZETIDIN-1-YL)PROP-2-EN-1-ONE DERIVATIVES AND SIMILAR COMPOUNDS AS KRAS G12C INHIBITORS FOR THE TREATMENT OF CANCER ARAXES PHARMA LLC (US) 2018-08-02 WO disclosed